To include your compound in the COVID-19 Resource Center, submit it here.

United Therapeutics' esuberaprost fails Phase III in PAH

United Therapeutics discontinued development of esuberaprost after the compound failed to meet

Read the full 126 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE